OCULHIGH SIGNALFINANCIAL10-K

OCUL's cash position substantially increased to $737M while operating losses and R&D spending grew meaningfully, indicating likely equity raise amid advancing clinical programs.

The company appears to have raised significant capital (cash nearly doubled) while substantially increasing R&D investment, suggesting acceleration of clinical development activities. However, operating losses expanded meaningfully alongside higher R&D spend, indicating the company is in a cash-intensive development phase that will require careful monitoring of burn rates.

Comparing 2026-02-05 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

OCUL's balance sheet strengthened considerably with cash increasing 88% to $737M and total assets growing 77%, likely from an equity raise. However, operational metrics deteriorated as R&D expenses grew substantially to $197M, driving operating losses meaningfully higher to $270M and operating cash outflows to $205M. The financial profile reflects a biotech company investing heavily in clinical development while maintaining a strong cash position to fund operations.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+88%
$392.1M→$737.1M

Cash position surged 88% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+77.4%
$441.0M→$782.1M

Current assets grew 77.4% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+76.5%
$457.9M→$808.1M

Asset base grew 76.5% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
+61.5%
$7.0M→$11.3M

Interest expense surged 61.5% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
-57.2%
-$171.8M→-$270.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+54.4%
$127.6M→$197.1M

R&D investment increased 54.4% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
-52.1%
-$134.7M→-$204.9M

Operating cash flow fell 52.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-37.4%
-$193.5M→-$265.9M

Net income declined 37.4% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+22.9%
$41.4M→$50.8M

Current liabilities rose 22.9% — increased short-term obligations, watch current ratio.

Inventory
Balance Sheet
+17.2%
$3.0M→$3.6M

Inventory built 17.2% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-05
PRIOR — 2025-03-03
ADDED
AXPAXLI is a trade name which we use to refer to our OTX-TKI product candidate.
Food and Drug Administration, or FDA, has not approved AXPAXLI as a product name.
Our net losses were $265.9 million and $193.5 million for the years ended December 31, 2025 and 2024, respectively.
As of December 31, 2025, we had an accumulated deficit of $1,157.0 million.
Clinical trials of our product candidates could produce negative or inconclusive results, or regulators could disagree with us regarding clinical trial results or the sufficiency of our proposed data package, for example if the FDA determines not to accept a new drug application for AXPAXLI for the treatment of wet AMD based on a single registrational trial, SOL-1, even if the data are positive, or in the alternative denies such application.
We are conducting our SOL-1 trial under a Special Protocol Assessment, or SPA, agreement, and, if needed, will conduct our HELIOS-2 trial under a SPA agreement, in each case agreed to by the FDA.
For instance, if DEXTENZA ceases to be eligible for reimbursement separate from ophthalmic surgery in the ambulatory surgical center setting or if we are not able to achieve the pricing and reimbursement coverage we anticipate for AXPAXLI, if approved, our net product revenues would be impacted significantly, and our ability to generate revenues from future sales of DEXTENZA or AXPAXLI could be adversely affected.
Depending on the outcome of our clinical programs, we will likely need additional funding to support future working capital needs and/or expansion of our operating plan.
Business We are an integrated biopharmaceutical company committed to redefining the retina experience.
AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology.
REMOVED
AXPAXLI is a trade name which we use to refer to our OTX-TKI product candidate, and PAXTRAVA is a trade name which we use to refer to our OTX-TIC product candidate.
Food and Drug Administration, or FDA, has not approved either AXPAXLI or PAXTRAVA as product names.
Ou r net losses were $ 193.5 million and $80.7 million for the y ears ended December 31, 2024 and 2023, respectively.
As of December 31, 2024, we had an accumulated deficit of $891.1 million.
If we raise additional funds through collaborations, strategic alliances, licensing arrangements, royalty agreements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, products or product candidates or grant licenses on terms that may not be favorable to us.
Clinical trials of our product candidates could produce negative or inconclusive results, or we could disagree with regulators regarding clinical trial results.
If we have a material disruption in our manufacturing operations at this facility, or if we are unable to obtain sufficient components of our products and product candidates from our suppliers on acceptable terms or at all, we may not have sufficient quantities of our product candidates to meet our clinical trial requirements or of our product inventory to meet our commercial requirements.
For instance, if DEXTENZA ceases to be eligible for reimbursement separate from ophthalmic surgery in the ambulatory surgical center setting, our net product revenues would decline significantly, and our ability to generate revenues from future sales of DEXTENZA would be adversely affected.
In addition, because the active pharmaceutical ingredients in our products and leading product candidates are available on a generic basis, competitors may be able to prepare and submit applications for abbreviated new drug applications, or ANDAs, or foreign equivalents for generic versions of our products without the need to conduct clinical development and may be able to offer and sell products, whether approved through the ANDA process or otherwise, with the same active pharmaceutical ingredient as our products so long as these competitors do not infringe our patent rights.
Business We are a biopharmaceutical company committed to redefining the retina experience.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →